Johannes Setijono - PT Kalbe President Commissioner
| PTKFF Stock | USD 0.09 0.00 0.00% |
President
Mr. Johannes Setijono serves as the President Commissioner of PT Kalbe Farma Tbk since May 26, 2008. He joined the Company in 1972 as Research Development Manager and was appointed as Director of Marketing in 1976. Between 1992 and 1998, he served as a Commissioner of the Company, as well as that of several other companies in the Kalbe Group, namely as Commissioner of PT Kageo Igar Jaya Tbk, President Commissioner of PT Hexpharm Jaya Laboratories and also as Commissioner PT Sanghiang Perkasa since 1993. Between 1996 and 1998, he served as President Director of PT Enseval Putera Megatrading Tbk. He was the President Commissioner of PT Bintang Toedjoe and a Commissioner of PT Finusolprima Farma. He has also held several senior positions in PT Dankos Laboratories Tbk, including as a Director in 1985, a Commissioner between 1989 and 1994 and President Commissioner from April 1994 until the merger. He also served as President Director of the Company from 1998 until May 26, 2008. He serves as Chairman of the Indonesian Pharmaceutical Association for the period from 2011 until 2016. He holds a degree in Pharmacy from Bandung Institute of Technology in 1969. He is the Chairman of Nomination and Remuneration Committees. since 2008.
| Age | 70 |
| Tenure | 16 years |
| Phone | 62 21 4287 3888 |
| Web | https://www.kalbe.co.id |
PT Kalbe Management Efficiency
The company has return on total asset (ROA) of 0.106 % which means that it generated a profit of $0.106 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1673 %, meaning that it generated $0.1673 on every $100 dollars invested by stockholders. PT Kalbe's management efficiency ratios could be used to measure how well PT Kalbe manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Leon Wang | AstraZeneca PLC ADR | N/A | |
| Jennifer Zachary | Merck Company | 46 | |
| Pam Cheng | AstraZeneca PLC ADR | 54 | |
| Andre Wyss | Novartis AG ADR | 50 | |
| Ruud Dobber | AstraZeneca PLC ADR | N/A | |
| Adele Ambrose | Merck Company | 59 | |
| Jeffrey Simmons | Eli Lilly and | 57 | |
| Mark Fishman | Novartis AG ADR | 63 | |
| Michael Harrington | Eli Lilly and | 55 | |
| Kathryn Wengel | Johnson Johnson | 55 | |
| Richard DeLuca | Merck Company | 61 | |
| Peter Fasolo | Johnson Johnson | 61 | |
| Sanat Chattopadhyay | Merck Company | 61 | |
| James Bradner | Novartis AG ADR | 49 | |
| Joshua Smiley | Eli Lilly and | 49 | |
| Fiona Marshall | Novartis AG ADR | 60 | |
| MarieFrance Tschudin | Novartis AG ADR | 53 | |
| Shreeram MD | Novartis AG ADR | 61 | |
| Barton Peterson | Eli Lilly and | 57 | |
| Myles ONeill | Eli Lilly and | 61 | |
| Adam Schechter | Merck Company | 52 | |
Management Performance
| Return On Equity | 0.17 | |||
| Return On Asset | 0.11 |
PT Kalbe Farma Leadership Team
Elected by the shareholders, the PT Kalbe's board of directors comprises two types of representatives: PT Kalbe inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PTKFF. The board's role is to monitor PT Kalbe's management team and ensure that shareholders' interests are well served. PT Kalbe's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PT Kalbe's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Djonny Tjahyadi, Director | ||
| Lanny Soputro, G HR | ||
| Ferdinand Aryanto, Commissioner | ||
| Santoso Oen, Commissioner | ||
| Ongkie Tedjasurja, Director | ||
| Sie Djohan, Management Devel | ||
| Bernadus Winata, Independent Director, Corporate Secretary | ||
| Johannes Setijono, President Commissioner | ||
| Bujung Nugroho, Director | ||
| Lucky Slamet, Independent Commissioner | ||
| Farid Moeloek, Independent Commissioner | ||
| Kurniawan Suhartono, Head Unit | ||
| Bernadette Setiady, President Director | ||
| Lilis Halim, Independent Commissioner | ||
| Bapak Vidjongtius, Corporate Secretary, Independent Director, Chairman of Good Corporate Governance Committee and Member of Bus. Risk Committee | ||
| Johanes Ibrahim, Independent Commissioner | ||
| Ronny Hadiana, Commissioner | ||
| Lukito Gozali, Head Relations |
PTKFF Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is PT Kalbe a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.17 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.12 % | |||
| Current Valuation | 6.11 B | |||
| Shares Outstanding | 46.26 B | |||
| Shares Owned By Insiders | 58.08 % | |||
| Shares Owned By Institutions | 15.23 % | |||
| Price To Book | 5.15 X | |||
| Price To Sales | 3.56 X | |||
| Revenue | 26.26 T |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as PT Kalbe Farma using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PT Kalbe Farma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the PT Kalbe Farma information on this page should be used as a complementary analysis to other PT Kalbe's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for PTKFF Pink Sheet analysis
When running PT Kalbe's price analysis, check to measure PT Kalbe's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PT Kalbe is operating at the current time. Most of PT Kalbe's value examination focuses on studying past and present price action to predict the probability of PT Kalbe's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PT Kalbe's price. Additionally, you may evaluate how the addition of PT Kalbe to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |